CF Foundation to Brief Congress on Its Pioneering Venture Philanthropy
June 27, 2007
On June 29, the Cystic Fibrosis Foundation and its largest biotechnology collaborator, Vertex Pharmaceuticals, will brief Congress on venture philanthropy and how the Foundation created and funds an innovative drug development program, which brings cystic fibrosis treatments to patients who need them.
The event, Breathing New Life Into Venture Philanthropy, will educate representatives about the CF Foundation’s visionary investment strategy for cystic fibrosis research.
With its innovative drug discovery and development pipeline, the Foundation has been a pioneer in collaborating with private sector programs and has set a new standard for investment in life-saving research.
Speakers will include:
- Robert J. Beall, Ph.D., president and CEO of the CF Foundation
- Joshua Boger, Ph.D., president and CEO of Vertex Pharmaceuticals,
a key partner in the drug pipeline
- Pamela L. Zeitlin, M.D., Ph.D., co-director of the CF Center
at Johns Hopkins University Hospital
The CF Foundation is grateful to the Congressional Cystic Fibrosis Caucus and its co-chairs, Reps. Edward Markey (D-MA) and Cliff Stearns (R-FL), for hosting this briefing. With more than 100 Members of Congress, the CF Caucus’ mission is to educate elected officials about cystic fibrosis and spur action on issues that concern the CF community.
To get involved in the CF Foundation’s advocacy efforts, contact (800) FIGHT CF or email@example.com.